Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.

By Jacob Bell • July 1, 2025

Sage to lay off most staff amid Supernus buyout

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by late August.

By Gwendolyn Wu • June 30, 2025

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Moderna flu shot outperforms marketed vaccines in large late-stage trial

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

By Jonathan Gardner • June 30, 2025

AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.

By Ned Pagliarulo • June 30, 2025

Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules

Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy for COVID-19 shots.

By BioPharma Dive staff • June 27, 2025

Vor, with new CEO, changes course to target autoimmune disease

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million in new funding.

By Gwendolyn Wu • June 26, 2025

Acadia’s ‘very bullish’ sales forecast restores some confidence on Wall Street

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.

By Jacob Bell • June 26, 2025

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a new drug prospect, meanwhile.

By Gwendolyn Wu • June 25, 2025

FDA investigating Elevidys safety; Nektar shares spike on eczema data

The agency said it will evaluate whether regulatory action is needed after investigating the deaths of two patients treated with Sarepta's therapy.

By BioPharma Dive staff • June 24, 2025

Lexeo to help launch spinout around RNA drugs for the heart

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely on viral vectors.

By Gwendolyn Wu • June 24, 2025

Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung cancer, a crowded indication with uncertain sales potential.

By Ben Fidler • June 24, 2025

Cidara stock soars as antiviral drug succeeds in flu study

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu prevention.

By Delilah Alvarado • June 23, 2025

Illumina to buy SomaLogic in deal worth up to $425M

Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene sequencing products.

By Susan Kelly • June 23, 2025

Prothena to lay off majority of staff; Zealand shares obesity drug data

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a dual-acting obesity drug and Biogen kicked off a new late-stage trial.

By BioPharma Dive staff • June 20, 2025

A longer ‘winter’: Public funding slowdown heightens pressure on biotech startups

A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on startups navigating a yearslong downturn.

By Gwendolyn Wu • June 20, 2025

FDA approves twice-yearly shot of Gilead drug for HIV prevention

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines. 

By Delilah Alvarado • June 18, 2025

Scholar Rock drug preserves muscle in obesity trial

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the company may look for a partner in obesity while focusing on rare diseases.

By Kristin Jensen • June 18, 2025

Draig, a brain drug startup, debuts with $140M to treat depression

The funds will support Phase 2 testing of a drug the company believes to be able to safely home in on AMPA receptors, an emerging but unproven depression target.

By Gwendolyn Wu • June 18, 2025

A startup banks $66M to pursue ‘inclusive precision medicine’

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of disease-causing genetic mutations in conditions like epilepsy and Charcot-Marie-Tooth disease.

By Gwendolyn Wu • June 18, 2025

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound. 

By BioPharma Dive staff • June 17, 2025

Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed in two earlier studies that missed their main goals.

By Jonathan Gardner • June 16, 2025

Sage, following setbacks, to sell to Supernus for $561M

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.

By Delilah Alvarado • June 16, 2025

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema. 

By Ben Fidler • June 16, 2025

BioNTech buys mRNA, courtroom rival CureVac in all-stock deal

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation. 

By Jonathan Gardner • June 13, 2025

Moderna wins FDA OK to widen use of RSV vaccine

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s been significantly impacted by the recent changes in FDA and HHS leadership.

By Delilah Alvarado • June 13, 2025